Molecular diagnostics is attracting more and more domestic and foreign companies to enter. PerkinElmer, Life Technologies and other multinational in vitro diagnostic companies, through mergers and acquisitions or joint ventures, develop the domestic molecular diagnostic market in depth. Domestic companies such as Da'an Gene and Kehua Biology have also increased their market expansion after the listing. Insiders said that the domestic molecular diagnostics market still has a lot of room for growth, and it is expected that more companies will join the competition in the future.

In recent years, molecular diagnostics has risen rapidly in the domestic market. In 2010, China's in vitro diagnostic market size was 2.07 billion US dollars (about 13.68 billion yuan), of which 5% of the share was occupied by emerging molecular diagnostics. Although the proportion of molecular diagnosis in China is not large at present, its average annual growth rate is twice that of the world, and it is the fastest growing field in in vitro diagnosis in China.

The fastest in vitro diagnostic subfield

Molecular diagnostics is also the fastest growing part of the global in vitro diagnostic market. Its share of in vitro diagnostics has increased from 2% in 1995 to 10% in 2009, with an annual growth rate of more than 10%.

In emerging markets, the growth rate of molecular diagnostics has attracted investors' attention. Among them, the annual growth rate of the molecular diagnostics market in China has reached more than 20%, which is twice that of the world. The market expects that by 2015, emerging market countries (mainly Latin America and the Pacific Rim) will be the main driving force for the growth of the molecular diagnostics market.

"It is precisely because of seeing the strong growth of emerging markets in the field of molecular diagnostics that the company is currently committed to developing analytical diagnostics in emerging markets, especially the Chinese market." Zhang Sheng, vice president of PerkinElmer Diagnostics Division, said that with the The increase in the elderly population, the transformation of the medical model, the increasing demand for molecular diagnostics in the social market, the molecular diagnostics market is facing unprecedented opportunities for development.

At present, products used for the treatment of infectious diseases are the main components of molecular diagnosis, accounting for about 50% of the total market; followed by blood screening, accounting for about 11%. The market predicts that molecular diagnostic techniques will be widely applied to personalized tumor treatment, expensive drug therapy monitoring, pharmacokinetic genomics, etc., POC testing, forensics, population health screening and physical examination, early warning and diagnosis of major diseases, public molecular genetic archives The application of establishment and other aspects has become the future development trend.

In the molecular diagnosis market for the treatment of infectious diseases, human immunodeficiency virus (HIV), hepatitis C virus (HCV), chlamydia trachomatis (CT), and Neisseria (NG) tests account for a major share. However, the market for molecular diagnostics of infectious diseases has been established, and market competition is extremely fierce, with fewer opportunities for new market competitors. The market for molecular diagnostic products tested by human papillomavirus (HPV) and methicillin-resistant Staphylococcus aureus (MRSA) is growing rapidly.

Blood screening has become the most concerned area in molecular diagnosis in China, and nucleic acid screening technology is the most popular among them. At present, the demand for blood screening in China is increasing at a rate of more than 15% per year. Shanghai Guoyuan Biotechnology Director Yang Guocui told reporters that relevant government departments attach great importance to blood nucleic acid screening projects. The Ministry of Health began to use nucleic acid technology to test all donated blood in the second half of 2010. It is expected that 80% coverage will be reached by the end of 2015 , To better ensure the quality and safety of the blood in the storage.

Ningbo Autrends International Trade Co.,Ltd. , https://www.supervapebar.com